# A rare presentation of CASPR2-associated Morvan syndrome overlapping with GM1-positive AMSAN: a case report

**Authors:** Yajing Wu, Xiaoli Tang, Tianyuan Guan, Jing Xu, Peiyuan Lv, Yanhong Dong

PMC · DOI: 10.3389/fimmu.2026.1755001 · Frontiers in Immunology · 2026-02-11

## TL;DR

A 70-year-old man showed rare overlapping symptoms of Morvan syndrome and AMSAN, both autoimmune nerve disorders, responding well to combined immunotherapy.

## Contribution

This case report highlights a rare coexistence of CASPR2-associated Morvan syndrome and GM1-positive AMSAN, suggesting shared immune mechanisms.

## Key findings

- The patient had anti-GM1 and anti-CASPR2 antibodies, indicating dual autoimmune involvement.
- Combined immunotherapy led to significant clinical improvement in the patient.
- The case suggests immune injury may involve both nodal and paranodal regions of peripheral nerves.

## Abstract

Morvan syndrome is a rare autoimmune disorder characterized by peripheral nerve hyperexcitability with autonomic and central nervous system involvement, most commonly associated with antibodies against contactin-associated protein-like 2 (CASPR2). Acute motor and sensory axonal neuropathy (AMSAN) is an axonal variant of Guillain–Barré syndrome linked to anti-ganglioside antibodies and often manifests as severe limb weakness. Their concurrent presentation is unusual and raises the possibility of shared immune targets within peripheral nerve microdomains.

A 70-year-old man presented with a relapsing course of progressive lower-limb weakness accompanied by widespread muscle twitching, severe insomnia with nocturnal hyperarousal, and refractory constipation. He had a prior episode diagnosed as AMSAN that improved after immunotherapy but relapsed four months after treatment was discontinued. Neurological examination demonstrated bilateral lower-limb weakness with reduced tendon reflexes. Moreover, electrophysiological studies confirmed diffuse multifocal peripheral nerve injury with superimposed peripheral nerve hyperexcitability. In addition, immunologic testing revealed serum anti-GM1 antibodies and anti-CASPR2 IgG in both serum and cerebrospinal fluid. Collectively, these findings supported a diagnosis of recurrent AMSAN coexisting with CASPR2-associated Morvan syndrome. Combined immunotherapy with corticosteroids and intravenous immunoglobulin, alongside symptomatic management, resulted in marked clinical improvement.

This case report describes a rare overlap of relapsing AMSAN and Morvan syndrome. This antibody-defined coexistence is hypothesis-generating and may reflect synergistic immune injury involving nodal and paranodal regions. This case underscores the importance of recognizing overlapping phenotypes to guide diagnostic profiling and immunomodulatory therapy.

## Linked entities

- **Proteins:** CNTNAP2 (contactin associated protein 2)
- **Diseases:** Morvan syndrome (MONDO:0008718), AMSAN (MONDO:0020348), Guillain–Barré syndrome (MONDO:0016218)

## Full-text entities

- **Genes:** CNTN2 (contactin 2) [NCBI Gene 6900] {aka AXT, EPEO5, FAME5, TAG-1, TAX, TAX1}, CNTNAP2 (contactin associated protein 2) [NCBI Gene 26047] {aka AUTS15, CASPR2, CDFE, NRXN4, PTHSL1}, SCN8A (sodium voltage-gated channel alpha subunit 8) [NCBI Gene 6334] {aka BFIS5, CERIII, CIAT, DEE13, EIEE13, MED}, LGI1 (leucine rich glioma inactivated 1) [NCBI Gene 9211] {aka ADLTE, ADPAEF, ADPEAF, DEE121, EPITEMPIN, EPT}, IL7 (interleukin 7) [NCBI Gene 3574] {aka IL-7, IMD130}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, KCNA2 (potassium voltage-gated channel subfamily A member 2) [NCBI Gene 3737] {aka DEE32, EIEE32, HBK5, HK4, HUKIV, KV1.2}, KCNA1 (potassium voltage-gated channel subfamily A member 1) [NCBI Gene 3736] {aka AEMK, EA1, HBK1, HUK1, KV1.1, MBK1}
- **Diseases:** inflammation (MESH:D007249), gastrointestinal symptoms (MESH:D012817), CIDP (MESH:D020277), trauma (MESH:D014947), hepatitis E (MESH:D016751), Epstein-Barr virus (MESH:D020031), peripheral nerve injury (MESH:D059348), antibody-mediated neuropathies (MESH:D020274), flu (MESH:D007251), Muscle (MESH:D019042), insomnia (MESH:D007319), AMSAN (MESH:D020275), limb weakness (MESH:D018908), sensory abnormalities (MESH:D012678), nodo-paranodopathy spectrum disorders (MESH:D063647), channelopathy (MESH:D053447), CNS injury (MESH:D002493), -associated disorder (MESH:D017096), cytomegalovirus (MESH:D003586), dysautonomia (MESH:D054969), MoS (OMIM:201300), autoimmune disorder (MESH:D001327), dengue (MESH:D003715), paralysis (MESH:D010243), hyporeflexia (MESH:D012021), seizures (MESH:D012640), nerve hyperexcitability (MESH:C537568), autonomic dysfunction (MESH:D001342), fasciculations (MESH:D005207), excessive daytime sleepiness (MESH:D006970), diarrheal illness (MESH:D004403), consciousness disturbances (MESH:D003244), infection (MESH:D007239), impaired attention (MESH:D001289), immune injury (MESH:D007154), nodal and paranodal dysfunction (MESH:D013611), pleocytosis (MESH:D007964), axonal degeneration (MESH:D009410), areflexia (MESH:D000071699), PNHS (MESH:D010523), thymoma (MESH:D013945), poliomyelitis (MESH:D011051), constipation (MESH:D003248), Zika (MESH:D000071243), neuromyotonia (MESH:D020386), axonal damage (MESH:D001480), neuropathy (MESH:D009422)
- **Chemicals:** Mycophenolate mofetil (MESH:D009173), glycosphingolipids (MESH:D006028), methylprednisolone (MESH:D008775), lipooligosaccharides (MESH:C023023), potassium (MESH:D011188), ganglioside (MESH:D005732), sodium (MESH:D012964), prednisone (MESH:D011241), lipid (MESH:D008055), Carbamazepine (MESH:D002220), Gabapentin (MESH:D000077206), calcium (MESH:D002118), heavy metal (MESH:D019216)
- **Species:** Mycoplasmoides pneumoniae (Filterable agent of primary atypical pneumonia, species) [taxon 2104], Campylobacter jejuni (species) [taxon 197], Homo sapiens (human, species) [taxon 9606], Bos taurus (bovine, species) [taxon 9913]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12932481/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12932481/full.md

## References

18 references — full list in the complete paper: https://tomesphere.com/paper/PMC12932481/full.md

---
Source: https://tomesphere.com/paper/PMC12932481